Anxiety Disorders - Pipeline Review, H1 2016

Description: Anxiety Disorders - Pipeline Review, H1 2016

Summary

‘Anxiety Disorders - Pipeline Review, H1 2016’, provides an overview of the Anxiety Disorders pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Anxiety Disorders, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Anxiety Disorders and features dormant and discontinued projects.

The report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Anxiety Disorders
- The report reviews pipeline therapeutics for Anxiety Disorders by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Anxiety Disorders therapeutics and enlists all their major and minor projects
- The report assesses Anxiety Disorders therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Anxiety Disorders

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Anxiety Disorders
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Anxiety Disorders pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Contents:

List of Tables
List of Figures
Introduction
Report Coverage
Anxiety Disorders Overview
Therapeutics Development
Pipeline Products for Anxiety Disorders - Overview
Pipeline Products for Anxiety Disorders - Comparative Analysis
Anxiety Disorders - Therapeutics under Development by Companies
Anxiety Disorders - Therapeutics under Investigation by Universities/Institutes
Anxiety Disorders - Pipeline Products Glance
Late Stage Products
Clinical Stage Products
Early Stage Products
Unknown Stage Products
Anxiety Disorders - Products under Development by Companies
Anxiety Disorders - Products under Investigation by Universities/Institutes
Anxiety Disorders - Companies Involved in Therapeutics Development
AbbVie Inc.
Ache Laboratorios Farmaceuticos S/A
Adamed Sp. z o.o.
Addex Therapeutics Ltd
Amorsa Therapeutics Inc.
Avineuro Pharmaceuticals, Inc.
Azevan Pharmaceuticals, Inc.
Bionomics Limited
Boehringer Ingelheim GmbH
C4X Discovery Holdings PLC
Catalyst Pharmaceutical Partners, Inc.
Edgemont Pharmaceuticals, LLC
Eisai Co., Ltd.
Eli Lilly and Company
F. Hoffmann-La Roche Ltd.
Gabather AB
GW Pharmaceuticals Plc
HolsboerMaschmeyer NeuroChemie GmbH
Humanetics Corporation
IntelGenx Corp.
Intra-Cellular Therapies, Inc.
INVENT Pharmaceuticals, Inc.
Marinus Pharmaceuticals, Inc.
Merz Pharma GmbH & Co. KgaA
MI.TO. Technology S.r.L.
Nemus Bioscience, Inc.
Neuralstem, Inc.
Neurelis, Inc.
NeuroNascent, Inc.
Newron Pharmaceuticals S.p.A.
Nippon Chemiphar Co., Ltd.
Novartis AG
Omeros Corporation
Otsuka Holdings Co., Ltd.
Pherin Pharmaceuticals, Inc.
Polleo Pharma Limited
Protagenic Therapeutics Inc.
Suda Ltd
Sumitomo Dainippon Pharma Co., Ltd.
Synchroneuron Inc.
Tonix Pharmaceuticals Holding Corp.
Trevena, Inc.
TRImaran Pharma, Inc.
Turing Pharmaceuticals AG
Vanda Pharmaceuticals Inc.

Anxiety Disorders - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type

Drug Profiles
18-MC - Drug Profile
acamprosate calcium SR - Drug Profile
ACH-36 - Drug Profile
ADN-2013 - Drug Profile
ADX-71441 - Drug Profile
ADX-71743 - Drug Profile
ADX-88178 - Drug Profile
alprazolam - Drug Profile
AM-3506 - Drug Profile
AVN-0189 - Drug Profile
AVN-101 - Drug Profile
AVN-628 - Drug Profile
BNC-210 - Drug Profile
brexpiprazole - Drug Profile
CPP-115 - Drug Profile
D-473 - Drug Profile

Drug for Post-Traumatic Stress Disorders - Drug Profile
Drugs to Modulate NPSR for Anxiety Disorder - Drug Profile
Drugs to Target HAT and HDAC for Alcohol Addiction and Anxiety Disorders - Drug Profile
E-2508 - Drug Profile
evenamide - Drug Profile
fluvoxamine maleate - Drug Profile
Gaaba-001 - Drug Profile
ganaxolone - Drug Profile
HL-9001 - Drug Profile
IC-87201 - Drug Profile
iloperidone - Drug Profile
INV-107 - Drug Profile
INV-170 - Drug Profile
ITI-007 - Drug Profile
ketamine hydrochloride - Drug Profile
lorazepam - Drug Profile
lorazepam ER - Drug Profile
loxapine succinate - Drug Profile
LSN-2535717 - Drug Profile
LY-2607540 - Drug Profile
mavoglurant - Drug Profile
midazolam hydrochloride - Drug Profile
MRZ-8676 - Drug Profile
nabiximols - Drug Profile
NB-51R1 - Drug Profile
NEO-1940 - Drug Profile
NNI-351 - Drug Profile
NSI-189 - Drug Profile
OMS-527 - Drug Profile
Peptide to Activate NPSR for Sleep Disorders and Anxiety Disorders - Drug Profile
PH-94B - Drug Profile
PT-00114 - Drug Profile
riluzole - Drug Profile
RO-646198 - Drug Profile
Rycal - Drug Profile
S-107 - Drug Profile
SCT-66 - Drug Profile
Small Molecule to Antagonize CRF-1 Receptor for Anxiety Disorders - Drug Profile
Small Molecule to Antagonize GPR31 for Anxiety Disorders - Drug Profile
Small Molecule to Target GPR151 for CNS Diseases - Drug Profile
Small Molecule to Target GPR22 for Anxiety, Cardiovascular Diseases and Osteoarthritis - Drug Profile
Small Molecule to Target GPR83 for CNS and Immunological Disorders - Drug Profile
Small Molecule to Target Oxytocin for Autism and Anxiety Disorders - Drug Profile
Small Molecules for Autism Spectrum Disorders and Obsessive Compulsive Disorders - Drug Profile
Small Molecules for Obsessive-Compulsive Disorder - Drug Profile
Small Molecules for Post-Traumatic Stress Disorder - Drug Profile
Small Molecules for Post-Traumatic Stress Disorder - Drug Profile
Small Molecules to Activate Sigma Receptor for Panic and Schizoaffective Disorders - Drug Profile
Small Molecules to Activate Translocator Protein for Anxiety - Drug Profile
Small Molecules to Activate TrkB Receptor for Central Nervous System, Metabolic Disorders and ENT Disorders - Drug Profile
Small Molecules to Agonize Beta3-Adrenoceptor for Anxiety, Depression and Overactive Bladder - Drug Profile
Small Molecules to Agonize D2 and Inhibit MAO for Depression and Anxiety - Drug Profile
Small Molecules to Agonize Delta Opioid Receptor for Anxiety and Depression - Drug Profile
Small Molecules to Antagonize CRHR1 for Depression and Anxiety Disorders - Drug Profile
Small Molecules to Antagonize mGlu2 for Anxiety and Depression - Drug Profile
Small Molecules to Antagonize mGluR3 for Anxiety and Depression - Drug Profile
Small Molecules to Antagonize mGluR7 For Central Nervous System Disorders - Drug Profile
Small Molecules to Antagonize mGluR7 for Post-Traumatic Stress Disorders and Acute Stress Disorder - Drug Profile
Small Molecules to Antagonize Orexin-1 Receptor for CNS Disorders - Drug Profile
Small Molecules to Antagonize TLR-4 for CNS Disorders - Drug Profile
Small Molecules to Inhibit TRPC4/C5 for Depression, Anxiety and Nephropathy - Drug Profile
Small Molecules to Modulate Mineralocorticoid Receptor for Depression and Anxiety - Drug Profile
Small Molecules to Target Nicotinic Acetylcholine Receptors for Anxiety Disorder - Drug Profile
SRX-246 - Drug Profile
STX - Drug Profile
TNX-102 - Drug Profile
Comparative Analysis by Late Stage Development, H1 2016
Comparative Analysis by Clinical Stage Development, H1 2016
Comparative Analysis by Early Stage Development, H1 2016
Comparative Analysis by Unknown Stage Development, H1 2016
Products under Development by Companies, H1 2016
Products under Development by Companies, H1 2016 (Contd..1)
Products under Development by Companies, H1 2016 (Contd..2)
Products under Development by Companies, H1 2016 (Contd..3)
Products under Development by Companies, H1 2016 (Contd..4)
Products under Investigation by Universities/Institutes, H1 2016
Products under Investigation by Universities/Institutes, H1 2016 (Contd..1)
Anxiety Disorders - Pipeline by AbbVie Inc., H1 2016
Anxiety Disorders - Pipeline by Ache Laboratorios Farmaceuticos S/A, H1 2016
Anxiety Disorders - Pipeline by Adamed Sp. z o.o., H1 2016
Anxiety Disorders - Pipeline by Addex Therapeutics Ltd, H1 2016
Anxiety Disorders - Pipeline by Amorsa Therapeutics Inc., H1 2016
Anxiety Disorders - Pipeline by Avineuro Pharmaceuticals, Inc., H1 2016
Anxiety Disorders - Pipeline by Azevan Pharmaceuticals, Inc., H1 2016
Anxiety Disorders - Pipeline by Bionomics Limited, H1 2016
Anxiety Disorders - Pipeline by Boehringer Ingelheim GmbH, H1 2016
Anxiety Disorders - Pipeline by C4X Discovery Holdings PLC, H1 2016
Anxiety Disorders - Pipeline by Catalyst Pharmaceutical Partners, Inc., H1 2016
Anxiety Disorders - Pipeline by Edgemont Pharmaceuticals, LLC, H1 2016
Anxiety Disorders - Pipeline by Eisai Co., Ltd., H1 2016
Anxiety Disorders - Pipeline by Eli Lilly and Company, H1 2016
Anxiety Disorders - Pipeline by F. Hoffmann-La Roche Ltd., H1 2016
Anxiety Disorders - Pipeline by Gabather AB, H1 2016
Anxiety Disorders - Pipeline by GW Pharmaceuticals Plc, H1 2016
Anxiety Disorders - Pipeline by HolsboerMaschmeyer NeuroChemie GmbH, H1 2016
Anxiety Disorders - Pipeline by Humanetics Corporation, H1 2016
Anxiety Disorders - Pipeline by IntelGenx Corp., H1 2016
Anxiety Disorders - Dormant Projects (Contd..1), H1 2016
Anxiety Disorders - Dormant Projects (Contd..2), H1 2016
Anxiety Disorders - Dormant Projects (Contd..3), H1 2016
Anxiety Disorders - Dormant Projects (Contd..4), H1 2016
Anxiety Disorders - Dormant Projects (Contd..5), H1 2016
Anxiety Disorders - Dormant Projects (Contd..6), H1 2016
Anxiety Disorders - Dormant Projects (Contd..7), H1 2016
Anxiety Disorders - Dormant Projects (Contd..8), H1 2016
Anxiety Disorders - Dormant Projects (Contd..9), H1 2016
Anxiety Disorders - Dormant Projects (Contd..10), H1 2016
Anxiety Disorders - Dormant Projects (Contd..11), H1 2016
Anxiety Disorders - Dormant Projects (Contd..12), H1 2016
Anxiety Disorders - Dormant Projects (Contd..13), H1 2016
Anxiety Disorders - Dormant Projects (Contd..14), H1 2016
Anxiety Disorders - Discontinued Products, H1 2016
Anxiety Disorders - Discontinued Products (Contd..1), H1 2016
Anxiety Disorders - Discontinued Products (Contd..2), H1 2016
Anxiety Disorders - Discontinued Products (Contd..3), H1 2016
Anxiety Disorders - Discontinued Products (Contd..4), H1 2016
Anxiety Disorders - Discontinued Products (Contd..5), H1 2016

List of Figures
Number of Products under Development for Anxiety Disorders, H1 2016
Number of Products under Development for Anxiety Disorders - Comparative Analysis, H1 2016
Number of Products under Development by Companies, H1 2016
Number of Products under Investigation by Universities/Institutes, H1 2016
Comparative Analysis by Clinical Stage Development, H1 2016
Comparative Analysis by Early Stage Products, H1 2016
Assessment by Monotherapy Products, H1 2016
Number of Products by Top 10 Targets, H1 2016
Number of Products by Stage and Top 10 Targets, H1 2016
Number of Products by Top 10 Mechanism of Actions, H1 2016
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2016
Number of Products by Routes of Administration, H1 2016
Number of Products by Stage and Routes of Administration, H1 2016
Number of Products by Molecule Types, H1 2016
Number of Products by Stage and Molecule Types, H1 2016

Ordering:

Order Online - http://www.researchandmarkets.com/reports/3691138/

Order by Fax - using the form below

Order by Post - print the order form below and send to

Research and Markets,
Guinness Centre,
Taylors Lane,
Dublin 8,
Ireland.
Fax Order Form
To place an order via fax simply print this form, fill in the information below and fax the completed form to 646-607-1907 (from USA) or +353-1-481-1716 (from Rest of World). If you have any questions please visit http://www.researchandmarkets.com/contact/

Order Information
Please verify that the product information is correct and select the format(s) you require.

Product Name: Anxiety Disorders - Pipeline Review, H1 2016
Web Address: http://www.researchandmarkets.com/reports/3691138/
Office Code: SC

Product Formats
Please select the product formats and quantity you require:

<table>
<thead>
<tr>
<th>Format</th>
<th>Quantity</th>
<th>Price</th>
</tr>
</thead>
<tbody>
<tr>
<td>Electronic (PDF) - Single User:</td>
<td></td>
<td>USD 2000</td>
</tr>
<tr>
<td>Electronic (PDF) - Site License:</td>
<td></td>
<td>USD 4000</td>
</tr>
<tr>
<td>Electronic (PDF) - Enterprisewide:</td>
<td></td>
<td>USD 6000</td>
</tr>
</tbody>
</table>

* The price quoted above is only valid for 30 days. Please submit your order within that time frame to avail of this price as all prices are subject to change.

Contact Information
Please enter all the information below in BLOCK CAPITALS

Title: Mr [ ] Mrs [ ] Dr [ ] Miss [ ] Ms [ ] Prof [ ]
First Name: ___________________________ Last Name: ___________________________
Email Address: * ___________________________
Job Title: ___________________________
Organisation: ___________________________
Address: ___________________________
City: ___________________________
Postal / Zip Code: ___________________________
Country: ___________________________
Phone Number: ___________________________
Fax Number: ___________________________

* Please refrain from using free email accounts when ordering (e.g. Yahoo, Hotmail, AOL)
Payment Information

Please indicate the payment method you would like to use by selecting the appropriate box.

☐ Pay by credit card: You will receive an email with a link to a secure webpage to enter your credit card details.

☐ Pay by check: Please post the check, accompanied by this form, to:

Research and Markets,
Guinness Center,
Taylors Lane,
Dublin 8,
Ireland.

☐ Pay by wire transfer: Please transfer funds to:

<table>
<thead>
<tr>
<th>Account number</th>
<th>833 130 83</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sort code</td>
<td>98-53-30</td>
</tr>
<tr>
<td>Swift code</td>
<td>ULSBIE2D</td>
</tr>
<tr>
<td>IBAN number</td>
<td>IE78ULSB98533083313083</td>
</tr>
<tr>
<td>Bank Address</td>
<td>Ulster Bank, 27-35 Main Street, Blackrock, Co. Dublin, Ireland.</td>
</tr>
</tbody>
</table>

If you have a Marketing Code please enter it below:

Marketing Code: ____________________________

Please note that by ordering from Research and Markets you are agreeing to our Terms and Conditions at http://www.researchandmarkets.com/info/terms.asp